Does a reasonable treatment approach beyond second-line exist?

由 Escudier, Bernard
出版 2013

Axitinib for the Management of Metastatic Renal Cell Carcinoma

由 Escudier, Bernard, Gore, Martin
出版 2012

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

由 Escudier, Bernard, Cosaert, Jan, Jethwa, Sangeeta
出版 2008

Non-Clear Cell Renal Cell Carcinoma: Does the Mammalian Target of Rapamycin Represent a Rational Therapeutic Target?

由 Albiges, Laurence, Molinie, Vincent, Escudier, Bernard
出版 2012

Non-Clear Cell Renal Cell Carcinoma: Does the Mammalian Target of Rapamycin Represent a Rational Therapeutic Target?

由 Albiges, Laurence, Molinie, Vincent, Escudier, Bernard
出版 2012

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

由 Mazza, Camille, Escudier, Bernard, Albiges, Laurence
發表在 Ther Adv Med Oncol (2016)

Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma Forum

由 Wood, Lori A, Escudier, Bernard, Reaume, Neil
出版 2007

Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma

由 Derosa, Lisa, Izzedine, Hassane, Albiges, Laurence, Escudier, Bernard
發表在 Oncol Rev (2016)

The Current and Evolving Landscape of First‐Line Treatments for Advanced Renal Cell Carcinoma

由 Calvo, Emiliano, Porta, Camillio, Grünwald, Viktor, Escudier, Bernard
發表在 Oncologist (2018)

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma

由 Motzer, Robert J., Escudier, Bernard, Gannon, Andrew, Figlin, Robert A.
發表在 Oncologist (2016)

HIF-2α/ITPR1 axis: A new saboteur of NK-mediated lysis

由 Messai, Yosra, Noman, Muhammad Zaeem, Hasmim, Meriem, Escudier, Bernard, Chouaib, Salem
發表在 Oncoimmunology (2015)

Progression-Free Survival (PFS) as a Surrogate Endpoint of Overall Survival (OS) in Patients with Metastatic Renal Cell Carcinoma (mRCC)

由 Halabi, Susan, Rini, Brian, Escudier, Bernard, Stadler, Walter M., Small, Eric J.
出版 2013

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

由 Motzer, Robert J., Escudier, Bernard, Powles, Thomas, Scheffold, Christian, Choueiri, Toni K.
發表在 Br J Cancer (2018)

Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape

由 Chouaib, Salem, Messai, Yosra, Couve, Sophie, Escudier, Bernard, Hasmim, Meriem, Noman, Muhammad Zaeem
出版 2012

Feasibility of nephron-sparing surgery in giant oncocytoma

由 Hajj, Albert El, Thanigasalam, Ruban, Boulay, Isabelle, Molinié, Vincent, Escudier, Bernard, Baumert, Hervé
出版 2014

A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma

由 Jobard, Elodie, Blanc, Ellen, Négrier, Sylvie, Escudier, Bernard, Gravis, Gwenaelle, Chevreau, Christine, Elena-Herrmann, Bénédicte, Trédan, Olivier
發表在 Br J Cancer (2015)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

由 Rochigneux, Philippe, Thomassin-Piana, Jeanne, Laibe, Sophy, Brunelle, Serge, Salem, Naji, Escudier, Bernard, Vassal, Gilles, Gravis, Gwenaelle
發表在 BMC Cancer (2018)

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

由 Mickisch, Gerald HJ, Schwander, Björn, Escudier, Bernard, Bellmunt, Joaquim, Maroto, José P, Porta, Camillo, Walzer, Stefan, Siebert, Uwe
出版 2011

Gynecologic bleeding revealing vaginal metastasis of renal cell carcinoma

由 Benbrahim, Zineb, Chouaib, Ali, Mazeron, Renaud, Leger-Ravet, Marie Bénédicte, Lefort, Catherine, Lhommé, Catherine, El Mesbahi, Omar, Escudier, Bernard
出版 2013

Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma

由 Guida, Annalisa, Le Teuff, Gwénaël, Alves, Carolina, Colomba, Emeline, Di Nunno, Vincenzo, Derosa, Lisa, Flippot, Ronan, Escudier, Bernard, Albiges, Laurence
發表在 Oncotarget (2020)